NCCN Guidelines® Insights - Kidney Cancer, Version 3.2015
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patients with clear cell carcinoma after first-line treatment with another tyrosine kinase inhibitor, and guidelines for follow-up of patients with renal cell carcinoma.
This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to NCCN Guidelines for Kidney Cancer
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Kidney Cancer
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician